Reprogramming the immune system to restore health in people suffering from autoimmune diseases
Joined January 2014
- Tweets 107
- Following 73
- Followers 199
- Likes 14
70 Photos and videos
What’s next for biotech innovation and immune tolerance? Join us at #BIO2026, where Dannielle Appelhans, CEO, and Adam Elhofy, CSO, will share insights on building transformative pipelines & new approaches for autoimmune disease treatment. Learn more: bit.ly/3Wty9Lo
12
Jun 10
In June, we join @MyastheniaOrg in recognizing #MGAwarenessMonth. We aim to help increase awareness for the myasthenia gravis community and reinforce the importance of continued research into autoimmune diseases and the underlying drivers of immune dysfunction. Learn more below.
Myasthenia gravis…
*Is a rare, neuromuscular, autoimmune condition
*Causes muscle weakness
*Can make it hard to see, swallow, breathe, and walk
*Can affect anyone, regardless of age, gender, or ethnicity
Learn more at
myasthenia.org/understanding…
1
38
Jun 8
At #FOCIS2026, we will present research that highlights our antigen-specific immune tolerance platform in autoimmune diseases, including clinical data from our trial in primary biliary cholangitis (PBC). Details in the graphic below. Visit our website: bit.ly/3OcleNn
54
Jun 1
Later this week, members of our team will present on our antigen-specific immune tolerance approach to #Type1Diabetes at the #ADASciSessions. See the graphic below for details, and learn more about our #T1D program by visiting our website: bit.ly/3Wty9Lo
2
64
May 20
On #ClinicalTrialsDay, we thank the patients, families, and healthcare professionals advancing research in type 1 diabetes (T1D). Without you, trials like ours could not move forward. Visit our new site for info about our trial: bit.ly/3Qod3OK
1
1
62
Apr 13
Attending @ImmunologyAAI’s #IMMUNOLOGY2026™? COUR’s Director of Immunology, Joseph Podojil, PhD, will present new data from our nanoparticle platform, including reversal of T1D in preclinical models. Learn more: courpharma.com/platform/ #AAI2026
1
1
2
100
Mar 24
Our Director of Immunology, Joe Podojil, PhD, will speak at the 8th Treg-Directed Therapies Summit on advancing antigen-specific, non-cell therapy approaches for autoimmune diseases and clinical data in #PrimaryBiliaryCholangitis & #CeliacDisease. Details: bit.ly/41YvX0x
2
54
Mar 20
March is #AutoimmuneAwarenessMonth and recognizing the millions living with #AutoimmuneDiseases. At COUR, we’re advancing antigen-specific tolerance therapies designed to address the root cause of autoimmune disease-not just their symptoms.
More here: ttps://bit.ly/3PxAGnn
1
47
Mar 3
One-year data from the Phase 2a trial of our investigational therapy CNP-104 show sustained benefit in #PrimaryBiliaryCholangitis (#PBC):
· Improved ALP and bilirubin levels
· Durable effects across liver stiffness
· Favorable safety and tolerability
More: bit.ly/4lcgO5g
72
Feb 26
Our VP of Research, Adam Elhofy, PhD, will present at the 9th Annual Antigen-Specific Immune Tolerance Summit. He will highlight clinical signatures of tolerance observed in our program for #PrimaryBiliaryCholangitis. Learn more: bit.ly/3MMZLJQ
43
Jan 28
Our recent publication in @ScienceMagazine defines how COUR nanoparticles (CNPs) induce antigen-specific immune tolerance by activating the same pathway the immune system uses to maintain self-tolerance during apoptotic cell clearance. Read more: bit.ly/4k8NMTt
1
3
62
Jan 21
We are enrolling adults in a #ClinicalTrial of CNP-106, an investigational, disease-specific immune therapy for #MyastheniaGravis. The study explores a targeted immune approach that aims to improve MG symptoms.
Learn more: bit.ly/4pDKPLP
2
64
22 Dec 2025
We are a proud partner of the 9th Annual ASIT Summit. We look forward to connecting with our peers and discussing the latest innovations in immune tolerance in March 2026. Our VP of Research, Adam Elhofy, PhD, will present. Details: bit.ly/3MMZLJQ
1
50
16 Dec 2025
We recently hosted the @ChiBiomed Entrepreneurial Fellows at our office. We discussed careers in biopharma and dug into the science behind our approach to antigen-specific immune tolerance. We are grateful for our collaboration and inspired by these future industry leaders.
45
5 Dec 2025
Join us in Phoenix, AZ at @MyastheniaOrg’s Community Health Fair on Saturday, December 6. Meet our team and learn about the ongoing #ClinicalTrial of our investigational antigen-specific treatment, CNP-106 for #MyastheniaGravis. Register here: bit.ly/4qbaooj
51
20 Nov 2025
We’re testing investigational therapy CNP-103 in a Phase 1/2 trial in patients with #Type1Diabetes as a novel approach to maintain insulin production by slowing the immune attack on beta cells. Learn more: bit.ly/40ptZqa
50
14 Nov 2025
Today is #WorldDiabetesDay. At COUR, we hope our work to develop an immune tolerance approach will one day make life easier for people managing #Type1Diabetes #T1D at work, at home & everywhere in between. Learn more about #WDD2025 #DiabetesLife campaign bit.ly/3M2xOx1
8
2
35
4 Nov 2025
We’re proud that COUR has been named one of @BioSpace’s 2026 Best Places to Work! Our team of curious, driven individuals bring creativity & collaboration to everything we do as we redefine what’s possible in the fight against autoimmune disease: bit.ly/4hRgqYc
39
31 Oct 2025
Don’t miss our two posters at @AASLDTweets’ #TLM25. The posters highlight data for our investigational tolerogenic therapy, CNP-104, which is being evaluated for the treatment of primary biliary cholangitis (PBC). Learn more about CNP-104 here: bit.ly/3Wty9Lo
1
1
1
160
13 Oct 2025
Team COUR was proud to join @BreakthroughT1D’s Chicago Walk last month in support of the #Type1Diabetes community. Together, we’re walking toward a future where innovative science and collective action will change lives for people with T1D.
39